Switch theme
Sign up to access all valuation multiples
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
2008
64
LTM Revenue $0.2M
Last FY EBITDA -$32.0M
$13.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sera Prognostics has a last 12-month revenue (LTM) of $0.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Sera Prognostics achieved revenue of $0.1M and an EBITDA of -$32.0M.
Sera Prognostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sera Prognostics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.2M | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | $30K | XXX | -$5K | XXX | XXX | XXX |
| Gross Margin | 16% | XXX | -6% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$32.0M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -41606% | XXX | XXX | XXX |
| EBIT | -$38.1M | XXX | -$36.6M | XXX | XXX | XXX |
| EBIT Margin | -20075% | XXX | -47578% | XXX | XXX | XXX |
| Net Profit | -$34.9M | XXX | -$32.9M | XXX | XXX | XXX |
| Net Margin | -18395% | XXX | -42725% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sera Prognostics's stock price is $2.
Sera Prognostics has current market cap of $58.8M, and EV of $13.1M.
See Sera Prognostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13.1M | $58.8M | XXX | XXX | XXX | XXX | $-0.95 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sera Prognostics has market cap of $58.8M and EV of $13.1M.
Sera Prognostics's trades at 170.7x EV/Revenue multiple, and -0.4x EV/EBITDA.
Equity research analysts estimate Sera Prognostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sera Prognostics has a P/E ratio of -1.7x.
See valuation multiples for Sera Prognostics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $58.8M | XXX | $58.8M | XXX | XXX | XXX |
| EV (current) | $13.1M | XXX | $13.1M | XXX | XXX | XXX |
| EV/Revenue | 69.2x | XXX | 170.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.4x | XXX | XXX | XXX |
| EV/EBIT | -0.3x | XXX | -0.4x | XXX | XXX | XXX |
| EV/Gross Profit | 438.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.7x | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSera Prognostics's last 12 month revenue growth is 444%
Sera Prognostics's revenue per employee in the last FY averaged $1K, while opex per employee averaged $0.6M for the same period.
Sera Prognostics's rule of 40 is -11088% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sera Prognostics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sera Prognostics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 444% | XXX | 410% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -41606% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -11088% | XXX | -41163% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7495% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 19130% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 47571% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sera Prognostics acquired XXX companies to date.
Last acquisition by Sera Prognostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Sera Prognostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sera Prognostics founded? | Sera Prognostics was founded in 2008. |
| Where is Sera Prognostics headquartered? | Sera Prognostics is headquartered in United States of America. |
| How many employees does Sera Prognostics have? | As of today, Sera Prognostics has 64 employees. |
| Who is the CEO of Sera Prognostics? | Sera Prognostics's CEO is Ms. Evguenia Lindgardt. |
| Is Sera Prognostics publicy listed? | Yes, Sera Prognostics is a public company listed on NAS. |
| What is the stock symbol of Sera Prognostics? | Sera Prognostics trades under SERA ticker. |
| When did Sera Prognostics go public? | Sera Prognostics went public in 2021. |
| Who are competitors of Sera Prognostics? | Similar companies to Sera Prognostics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Sera Prognostics? | Sera Prognostics's current market cap is $58.8M |
| What is the current revenue of Sera Prognostics? | Sera Prognostics's last 12 months revenue is $0.2M. |
| What is the current revenue growth of Sera Prognostics? | Sera Prognostics revenue growth (NTM/LTM) is 444%. |
| What is the current EV/Revenue multiple of Sera Prognostics? | Current revenue multiple of Sera Prognostics is 69.2x. |
| Is Sera Prognostics profitable? | Yes, Sera Prognostics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
